Target General Infomation
Target ID
T76093
Former ID
TTDNC00420
Target Name
HB-EGF
Gene Name
HBEGF
Synonyms
DTR; Heparinbinding EGFlike growth factor; Proheparinbinding EGFlike growth factor; HBEGF
Target Type
Clinical Trial
Disease Ovarian cancer [ICD9: 183; ICD10: C56]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Function
Growth factor that mediates its effects via EGFR,ERBB2 and ERBB4. Required for normal cardiac valve formation and normal heart function. Promotes smooth muscle cell proliferation. May be involved in macrophage-mediated cellular proliferation. It ismitogenic for fibroblasts, but not endothelial cells. It is able to bind EGF receptor/EGFR with higher affinity than EGF itself and is a far more potent mitogen for smooth muscle cells than EGF. Alsoacts as a diphtheria toxin receptor.
BioChemical Class
Growth factor
UniProt ID
Sequence
MKLLPSVVLKLFLAAVLSALVTGESLERLRRGLAAGTSNPDPPTVSTDQLLPLGGGRDRK
VRDLQEADLDLLRVTLSSKPQALATPNKEEHGKRKKKGKGLGKKRDPCLRKYKDFCIHGE
CKYVKELRAPSCICHPGYHGERCHGLSLPVENRLYTYDHTTILAVVAVVLSSVCLLVIVG
LLMFRYHRRGGYDVENEEKVKLGMTNSH
Drugs and Mode of Action
Drug(s) KHK-2866 Drug Info Phase 1 Ovarian cancer [523323]
U3-1565 Drug Info Phase 1 Solid tumours [523347]
Modulator U3-1565 Drug Info [549680]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway ErbB signaling pathway
GnRH signaling pathway
Estrogen signaling pathway
Epithelial cell signaling in Helicobacter pylori infection
Proteoglycans in cancer
NetPath Pathway IL5 Signaling Pathway
IL1 Signaling Pathway
EGFR1 Signaling Pathway
TNFalpha Signaling Pathway
PANTHER Pathway EGF receptor signaling pathway
CCKR signaling map ST
Pathway Interaction Database ErbB4 signaling events
LPA receptor mediated events
Plasma membrane estrogen receptor signaling
ErbB receptor signaling network
Reactome SHC1 events in ERBB2 signaling
PI3K events in ERBB4 signaling
SHC1 events in ERBB4 signaling
Nuclear signaling by ERBB4
PIP3 activates AKT signaling
GRB2 events in ERBB2 signaling
PI3K events in ERBB2 signaling
EGFR Transactivation by Gastrin
Constitutive Signaling by Aberrant PI3K in Cancer
RAF/MAP kinase cascade
WikiPathways ErbB Signaling Pathway
Hypertrophy Model
NRF2 pathway
Nuclear Receptors Meta-Pathway
IL1 and megakaryotyces in obesity
Signaling by ERBB4
Signaling by ERBB2
Gastrin-CREB signalling pathway via PKC and MAPK
PIP3 activates AKT signaling
References
Ref 523323ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health.
Ref 523347ClinicalTrials.gov (NCT01290471) Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors. U.S. National Institutes of Health.
Ref 523323ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health.
Ref 549680J Clin Oncol 31, 2013 (suppl; abstr 2519).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.